Hepatitis c Trials in Bakersfield, United States
Conditions / Hepatitis c / Bakersfield, United States
Hepatitis c is a medical condition with active clinical research programs worldwide.
15 total trials for this combination
Showing top 10 of 15 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01297270 | Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2) | COMPLETED | PHASE3 |
| NCT01281423 | Safety and Efficacy of ANA598 Administered With Pegylated Interferon and Ribavirin in Genotype-1 Patients With Chronic HCV Infection | UNKNOWN_STATUS | PHASE2 |
| NCT01323244 | A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study | COMPLETED | PHASE3 |
| NCT01467479 | A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV) | TERMINATED | PHASE3 |
| NCT01281839 | An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy | COMPLETED | PHASE3 |
| NCT01497366 | Phase 3 Study of Sofosbuvir and Ribavirin | COMPLETED | PHASE3 |
| NCT01485991 | TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy | COMPLETED | PHASE3 |
| NCT01289782 | An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients | COMPLETED | PHASE3 |
| NCT01500772 | Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C | TERMINATED | PHASE3 |
| NCT01349465 | 3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection | COMPLETED | PHASE3 |